Mitsubishi Tanabe Awarded $117 Million And A Lower Price In Remicade Supply Price Dispute With J&J
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma Corp. announced Aug. 8 it was awarded $117 million in an arbitration decision by the International Chamber of Commerce in a five-year disputed with Johnson & Johnson’s Janssen Biotech, Inc. over the supply price of Remicade (infliximab).